Cytosorbents Corp (NASDAQ: CTSO)

CytoSorbents is a leader in the treatment of life threatening conditions in the intensive care unit and cardiac surgery through blood purification. The company develops and commercializes cartridge based therapies that use biocompatible porous polymer beads to remove toxins cytokines and inflammatory mediators from blood. Its technology can be used with standard hospital pumps such as dialysis machines continuous renal replacement therapy extracorporeal membrane oxygenation and heart lung machines. The primary markets are critical care cardiac surgery and organ transplant.

CytoSorbents generates revenue mainly from the sale of its blood purification cartridges and related devices. The principal products are CytoSorb for critical care and cardiac surgery ECOS 300CY for ex vivo organ perfusion VetResQ for veterinary use and the PuriFi hemoperfusion pump. The company also receives royalty payments from licensing agreements and has earned cumulative sales of approximately $285.3 million from CytoSorb since its launch. Sales occur through direct channels and distributors in more than seventy countries worldwide.

CytoSorbents holds a leading position in the acute care blood purification market due to its proprietary porous polymer bead technology that removes a broad range of mid sized molecules not cleared by dialysis. The company’s products have received CE mark approval in the European Union and have been granted two FDA breakthrough device designations for the DrugSorb ATR system targeting ticagrelor and direct oral anticoagulant removal. Competitors in the cytokine adsorption space include Oxiris SepteX PMMA HA330 HA380 and others but CytoSorbents differentiates itself through ease of use high flow capability and a growing body of peer reviewed publications supporting clinical benefit.

CytoSorbents serves hospitals intensive care units cardiac surgery centers transplant facilities and veterinary clinics. Its products are used in clinical settings across North America Europe Asia and the Middle East. While the filing does not disclose specific customer names the company collaborates with partners such as Fresenius Medical Care B Braun Aferetica and Terumo for distribution and marketing.